Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study

MLA

M. Stoll, et al. “Neoadjuvant Bevacizumab, Docetaxel and Capecitabine Combination Therapy for HER2/Neu-Negative Invasive Breast Cancer: Efficacy and Safety in a Phase II Pilot Study.” European Journal of Surgical Oncology : The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, vol. 35, no. 10, Oct. 2008. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....7ed9a3f409e5b74266a3ec3d4efaf9ea&authtype=sso&custid=ns315887.

APA

M. Stoll, B. Mlineritsch, Christian Menzel, Roland Reitsamer, Martin Moik, S. Ressler, R. Greil, & K. Namberger. (2008). Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study. European Journal of Surgical Oncology : The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 35(10).

Chicago

M. Stoll, B. Mlineritsch, Christian Menzel, Roland Reitsamer, Martin Moik, S. Ressler, R. Greil, and K. Namberger. 2008. “Neoadjuvant Bevacizumab, Docetaxel and Capecitabine Combination Therapy for HER2/Neu-Negative Invasive Breast Cancer: Efficacy and Safety in a Phase II Pilot Study.” European Journal of Surgical Oncology : The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 35 (10). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....7ed9a3f409e5b74266a3ec3d4efaf9ea&authtype=sso&custid=ns315887.